Immunodermatology News

A study involving more than 4,000 twins showed that hidradenitis suppurativa disease pathogenesis may be more genetically driven than previously thought.

Patients with hidradenitis suppurativa are more likely to have substance-related disorders as well as psychiatric disorders, according to a presentation at the European Academy of Dermatology and Venereology congress.

The first adult patient has been dosed in a phase 1/2 clinical trial of FCX-013 for the treatment of scleroderma, Castle Creek Biosciences announced in a press release.

A multidisciplinary approach is key to optimizing outcomes in systemic sclerosis, given the broad range of manifestations and organ systems that may be involved, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Improvement in pain associated with hidradenitis suppurativa was seen with ertapenem therapy, but relief was short-lived, according to a poster presented at the American Academy of Dermatology virtual meeting.

Patients with autoimmune bullous diseases often experience negative impacts on their sexual quality of life, according to a poster presented at the American Academy of Dermatology virtual meeting.

Avita Therapeutics has enrolled the first patient in a pivotal study of its Recell system for the treatment of stable vitiligo, the company announced in a press release.

Many drugs can induce cutaneous or systemic lupus erythematosus, and physicians should be aware of the evolving drug association list, according to a study.

Quality of life is impaired with negative psychological health outcomes in patients with immunobullous dermatoses, and systemic corticosteroids may increase these risks, according to a poster presentation.

Although systemic sclerosis treatments have often been stymied in clinical development, a trio of “interesting future therapies” may offer new options, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.